Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

A team of international researchers led by scientists at City of Hope®, one of the largest and most advanced cancer research ...

The EMA has given a positive opinion for the exceptional circumstances authorization of Imreplys (sargramostim) to treat myelosuppression after acute radiation exposure.

Research discoveries leading to the development of new pharmaceutical compounds are notoriously difficult to translate into clinical practice.1 Drug repurposing provides a strategy to identify ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

Drug resistance in solid tumors remains a major obstacle in oncology, frequently leading to treatment failure and disease relapse. A central contributor to ...

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.